Trial Profile

Phase I Study of MOC31-PE in Antigen Positive Carcinomas.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Monoclonal antibody moc 31 PE conjugate (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

10 Nov 2015 Results published in the British Journal of Cancer
03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
03 May 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com